Germany updates: Lawmaker warns airports over drone threat

The German pharmaceutical industry has strongly warned against proposed 100% US tariffs on medicines, stating such measures would severely impact its €27 billion export market to the US, disrupt supply chains, and freeze investments, while contradicting existing EU-US trade agreements. Concurrently, Chancellor Friedrich Merz advocated for greater European digital sovereignty, urging a reduction in reliance on US software and the development of domestic data infrastructure.

Analysis

A proposed 100% US tariff on medicines, set for implementation on October 1st, presents a significant headwind for the German pharmaceutical industry. The tariff directly threatens a critical export market, which accounted for €27 billion, or roughly 25% of Germany's total pharmaceutical exports in 2024. The German Association of Research-Based Pharmaceutical Companies (VFA) has quantified the immediate impact, reporting that investments within Germany are already being frozen in anticipation of the measures. This policy, which contravenes a prior US-EU agreement capping such tariffs at 15%, is expected to disrupt international supply chains, escalate production costs, and potentially compromise patient care. The announcement includes an exemption for companies that invest in US-based manufacturing, creating a significant strategic dilemma for firms like Bayer and Merck. This trade friction is echoed in other policy discussions, with Chancellor Friedrich Merz simultaneously urging for greater European digital sovereignty to reduce reliance on US technology, signaling a broader trend of strategic decoupling that extends beyond the healthcare sector.

Key Decisions for Investors

• Investors with exposure to the European healthcare sector should immediately assess the revenue concentration of German pharmaceutical companies in the US market, given that 25% of the country's pharma exports are at risk.
• It is critical to monitor communications from major German pharmaceutical firms for their strategic response, particularly regarding any plans to shift capital expenditures toward US-based production to secure tariff exemptions.
• The combined threat of pharmaceutical tariffs and calls for European digital sovereignty indicates elevated transatlantic trade risk, warranting a broader portfolio review for exposure to other German and EU export-oriented sectors.